Tirzepatide: what 72 weeks of treatment looks like
A dual-hormone medication and, by the published numbers, among the most effective options a provider can prescribe today. This page walks through the real shape of treatment — the five-month dose build, the level your body carries between shots, and what the pivotal trial measured.
Zepbound / Mounjaro · dual GIP/GLP-1 receptor agonist, once-weekly injection[1]
What treatment actually looks like
You inject once a week, and the schedule in front of you is longer than most people expect: reaching the highest maintenance dose takes about five months of stepwise increases, each held for at least four weeks. That pace is the treatment working as designed — the trial results below were produced by exactly this kind of patient, gradual protocol, not by rushing to the top dose. Along the way your provider adjusts based on how you respond; plenty of people do well at the middle maintenance doses and never need the highest one.
How the dose builds
Per the FDA label, treatment starts at 2.5 mg weekly for four weeks — a tolerability dose — then moves to 5 mg. From there, increases come in 2.5 mg steps with at least four weeks at each level, toward a maintenance dose of 5, 10, or 15 mg. The schedule below shows the fastest labeled path to 15 mg; a provider may stop at a lower maintenance dose or hold steps longer.[2]
Doses step up gradually so the body can adjust — moving up is never automatic. A provider confirms each step based on how treatment is going, and slower schedules are common when side effects need more time to settle.
Medication level and measured weight change, together
The teal line models the medication itself: with a half-life around five to six days, each weekly shot builds on the residue of the last, and every escalation step raises the running level to a new plateau — which is why effects deepen for months. The green line is the SURMOUNT-1 trial's measured average weight change for the 15 mg group over 72 weeks, with placebo dashed underneath.[1]
Teal line: an illustrative pharmacokinetic model of once-weekly Tirzepatide following the labeleddose-escalation schedule (relative units — the shape, not a measurement). Green line: mean body-weight change reported in SURMOUNT-1 (15 mg arm, n=630, of 2,539 randomized). The weekly curve is the trial's efficacy-estimand series (reaching -22.5% at week 72); the trial's primary treatment-regimen estimate, which counts everyone regardless of whether they stayed on treatment, was -20.9%. Intermediate points are approximate readings from the published figure. Study means describe study populations — individual results vary, and treatment decisions belong to you and a licensed provider.
What the research measured
SURMOUNT-1 enrolled 2,539 adults with obesity (or overweight plus a weight-related condition) and no diabetes. At week 72, average weight change was 15.0% at the 5 mg dose, 19.5% at 10 mg, and 20.9% at 15 mg, versus 3.1% with placebo. Nine in ten participants on 15 mg lost at least 5% of their body weight.[1]
Side effects, honestly
- Gastrointestinal effects lead the list — nausea, diarrhea, vomiting, constipation — concentrated around dose increases and generally easing as the body adapts.
- The label carries a boxed warning about thyroid C-cell tumors observed in rodents; a personal or family history of medullary thyroid carcinoma or MEN 2 rules it out.
- Serious but less common risks include pancreatitis and gallbladder disease; severe gastrointestinal illness is a reason to contact your provider promptly.
- It is not combined with other GLP-1-class medications, and kidney function can suffer if dehydration from GI side effects goes unmanaged — fluids matter.
Source: FDA prescribing information[2]. Not a complete list — a provider reviews your health history before any prescription.
Common questions
How is tirzepatide different from semaglutide?
Tirzepatide activates two gut-hormone receptors (GIP and GLP-1) rather than one. In their separate pivotal trials — which enrolled different people and ran different lengths, so the comparison is indirect — tirzepatide's average weight loss at the top dose was larger. A head-to-head choice is a conversation with your provider about your health history, tolerability, and cost.
Do I have to reach 15 mg for it to work?
No. The label defines 5, 10, and 15 mg as maintenance doses, and the trial showed substantial average weight loss at every one of them. Your provider tunes the dose to your response and side effects, not to a leaderboard.
Why does the full effect take so long?
Two clocks run at once: the dose-escalation schedule takes about five months to reach the top maintenance dose, and average weight change in the trial kept deepening well past a year. The chart on this page shows both clocks together.
Is Zepbound the same as Mounjaro?
Both are tirzepatide. Zepbound is the FDA-approved formulation for chronic weight management; Mounjaro is approved for type 2 diabetes. Which is appropriate — and whether either is — is a licensed provider's call.
Wondering if tirzepatide is right for you?
A licensed provider reviews your health history and gives you a straight answer — including no, when it's the right answer.
References
- 1.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. doi:10.1056/NEJMoa2206038. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- 2.ZEPBOUND (tirzepatide) injection — FDA Prescribing Information, via DailyMed (dosage & administration; clinical pharmacology). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
This page is educational information, not medical advice, and reading it does not create a provider relationship. Whether any medication is appropriate for you is a decision for you and a licensed clinician who knows your health history. Study results describe study populations under trial conditions; individual results vary. If you experience concerning symptoms while on any medication, contact your clinician or seek urgent care.